About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

More Accurate Diagnosis With New Prostate Cancer Test

by Thilaka Ravi on April 7, 2011 at 10:52 PM
Font : A-A+

 More Accurate Diagnosis With New Prostate Cancer Test

In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer, especially the aggressive form of the disease. It also substantially reduced false positives compared to the twocurrently available commercial PSA tests, according to newly published research from Northwestern Medicine.

The only currently available Food and Drug Administration-approved screening tests for prostate cancer result in a high number of false positives and lead to unnecessary biopsies and possible over-detection and over-treatment of indolent cancer which never would have caused suffering or death.

Advertisement

PSA stands for prostate-specific antigen, a substance whose elevated levels can indicate prostate cancer but can also be caused by prostate inflammation or enlargement or other conditions. Its lack of specificity can result in unnecessary biopsies.

"This new test is more specific and accurate than the currently available blood tests for early prostate cancer detection," said lead investigator William Catalona, M.D., director of the clinical prostate cancer program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "This will focus on the detection of more life-threatening prostate cancers and reduce unnecessary biopsies in men 50 years of age and older."
Advertisement

Catalona, known as the father of the PSA screening, was the first to show in 1991 that a simple blood test measuring PSA levels could be used to detect prostate cancer. He is a professor of urology at Northwestern's Feinberg School of Medicine and a urologist atNorthwestern Memorial Hospital.

The study, which will be published in the May issue of the Journal of Urology, followed 900 patients from 10 sites, including Northwestern. The results showed the new screening test, a simple blood test called the Pro-PSA test, is particularly useful for patients with a normal prostate exam whose PSA is 2 to 10, a range considered thediagnostic gray zone because most men with higher levels have prostate cancer and most men with lower levels do not.

The Pro-PSA test measures a more specific PSA subform called (-2) Pro-PSA. The test becomes even more accurate when its results are analyzed with a mathematical formula that provides an overall Prostate Health Index. (The formula divides the Pro-PSA number by the free-PSA. Then the quotient of the two is multiplied by the square root of the total PSA. )

"The logic behind the formula is that the higher the Pro-PSA and the total PSA and the lower the free-PSA, the more likely the patient has aggressive prostate cancer," Catalona said.

The new Pro-PSA test was recently approved for commercial use in Europe, Catalona noted. "The FDA is currently reviewing our data from the study, and I'm hopeful that it will be approved in the United States as well," he said.
Source: Eurekalert
Advertisement
Advertisement
Advertisement

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

More Accurate Diagnosis With New Prostate Cancer Test Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests